 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...201202203204205206207208209210211...235236» |
- Modufolin (arfolitixorin) / Isofol Medical, Solasia
Trial primary completion date: Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX. (clinicaltrials.gov) - Feb 24, 2016
P1/2, N=6, Recruiting, Sponsor: Isofol Medical AB
Trial primary completion date: Oct 2015 --> Mar 2017
- |||| Trial primary completion date, Combination therapy, Metastases: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 24, 2016
P3, N=627, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Oct 2015 --> Mar 2017 Trial primary completion date: Jan 2008 --> Aug 2006
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment change, Trial primary completion date: PePiTA: Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer (clinicaltrials.gov) - Feb 24, 2016
P=N/A, N=205, Recruiting, Sponsor: Jules Bordet Institute
Trial primary completion date: Jan 2008 --> Aug 2006 N=135 --> 205 | Trial primary completion date: Nov 2015 --> Dec 2016
- || Vectibix (panitumumab) / Amgen
Trial primary completion date: STEPP: Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy (clinicaltrials.gov) - Feb 23, 2016
P2, N=95, Completed, Sponsor: Amgen
N=135 --> 205 | Trial primary completion date: Nov 2015 --> Dec 2016 Trial primary completion date: Oct 2008 --> Jan 2008
- ||||||| leucovorin calcium / Generic mfg., thioguanine / Generic mfg.
Trial completion: Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 23, 2016
P3, N=3054, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Oct 2008 --> Jan 2008 Active, not recruiting --> Completed
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial: Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer (clinicaltrials.gov) - Feb 23, 2016
P2, N=50, Recruiting, Sponsor: Chinese Academy of Medical Sciences
- Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Enrollment open, Trial initiation date, Trial primary completion date: FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 21, 2016
P2, N=25, Recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Feb 2016 | Trial primary completion date: Jul 2018 --> Feb 2018
- oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Enrollment closed, Enrollment change: Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study (clinicaltrials.gov) - Feb 18, 2016
P2, N=1, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Feb 2016 | Trial primary completion date: Jul 2018 --> Feb 2018 Recruiting --> Active, not recruiting | N=32 --> 1
- EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Trial suspension, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: NCI-2015-01942: BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer (clinicaltrials.gov) - Feb 18, 2016
P1/2, N=43, Suspended, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Active, not recruiting | N=32 --> 1 Recruiting --> Suspended
- || Zaltrap (ziv-aflibercept IV) / Sanofi
Trial primary completion date, Metastases: Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR). (clinicaltrials.gov) - Feb 17, 2016
P2, N=80, Recruiting, Sponsor: Centre Oscar Lambret
Recruiting --> Suspended Trial primary completion date: Oct 2016 --> Jul 2017
- Trial primary completion date, Metastases: Molecularly Tailored Therapy for Pancreas Cancer (clinicaltrials.gov) - Feb 17, 2016
P2, N=20, Active, not recruiting, Sponsor: Georgetown University
Trial primary completion date: Oct 2016 --> Jul 2017 Trial primary completion date: Dec 2015 --> Jun 2016
- || telisotuzumab (h224G11) / AbbVie
Trial primary completion date, Metastases: Study of ABT-700 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Feb 17, 2016
P1, N=124, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Dec 2015 --> Apr 2016
- Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial primary completion date, Combination therapy, Metastases: MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 16, 2016
P1, N=34, Recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Dec 2015 --> Apr 2016 Trial primary completion date: Jun 2016 --> Dec 2016
- Trial primary completion date: Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Feb 12, 2016
P=N/A, N=42, Active, not recruiting, Sponsor: Philip Philip
Trial primary completion date: Jun 2016 --> Dec 2016 Trial primary completion date: Sep 2015 --> Sep 2016
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Metastases: Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer (clinicaltrials.gov) - Feb 12, 2016
P1/2, N=44, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Apr 2016 --> Apr 2017
- NN1213 / Novo Nordisk
Trial primary completion date: A Study in Adults With Untreated Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 12, 2016
P2, N=100, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Apr 2016 --> Apr 2017 Trial primary completion date: Dec 2015 --> Dec 2016
- | Enrollment change: Mature B-Cell Lymphoma And Leukemia Study III (clinicaltrials.gov) - Feb 12, 2016
P2/3, N=122, Recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Dec 2015 --> Dec 2016 N=60 --> 122
- | Enrollment open: ESOPEC: Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus (clinicaltrials.gov) - Feb 12, 2016
P3, N=438, Recruiting, Sponsor: University Hospital Freiburg
N=60 --> 122 Not yet recruiting --> Recruiting
- Enrollment open, Trial initiation date, Trial primary completion date: Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma (clinicaltrials.gov) - Feb 12, 2016
P2, N=30, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Dec 2015 | Trial primary completion date: Jan 2017 --> Jan 2018
- ||| Stivarga (regorafenib) / Bayer
Enrollment closed, Enrollment change, Combination therapy, Metastases: Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 11, 2016
P2, N=181, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Dec 2015 | Trial primary completion date: Jan 2017 --> Jan 2018 Recruiting --> Active, not recruiting | N=240 --> 181
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment change, Trial termination: PRIMM: Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer (clinicaltrials.gov) - Feb 10, 2016
P2, N=3, Terminated, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Recruiting --> Active, not recruiting | N=240 --> 181 N=40 --> 3 | Recruiting --> Terminated; Recruitment difficulties
- Farydak (panobinostat) / Secura Bio
New P1/2 trial, Combination therapy: Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 8, 2016
P1/2, N=36, Not yet recruiting, Sponsor: St. Jude Children's Research Hospital
- |||| Avastin (bevacizumab) / Roche
Enrollment open, Combination therapy, Metastases: FABLOx: Study of 5-fluorouracil (5-FU), Nab (clinicaltrials.gov) - Feb 8, 2016
P1/2, N=78, Recruiting, Sponsor: Celgene Corporation
N=40 --> 3 | Recruiting --> Terminated; Recruitment difficulties Not yet recruiting --> Recruiting
- || Graspa (eryaspase) / PHAXIAM Therap
Trial primary completion date, Metastases: Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma (clinicaltrials.gov) - Feb 5, 2016
P2, N=90, Recruiting, Sponsor: ERYtech Pharma
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2015 --> Apr 2016
- Erbitux (cetuximab) / Eli Lilly
Enrollment change, Metastases: TIME-PRODIGE 28: Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC) (clinicaltrials.gov) - Feb 5, 2016
P2, N=168, Recruiting, Sponsor: UNICANCER
Trial primary completion date: Sep 2015 --> Apr 2016 N=136 --> 168
- |||||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Mismatch repair, Microsatellite instability, Metastases: Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) (clinicaltrials.gov) - Feb 5, 2016
P3, N=270, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=136 --> 168 Not yet recruiting --> Recruiting
- EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Enrollment closed, Trial primary completion date, IO biomarker, Metastases: Anti-CD3 x Anti-Erbitux (clinicaltrials.gov) - Feb 4, 2016
P1, N=30, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Jul 2016
- EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Enrollment open, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: NCI-2015-01942: BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer (clinicaltrials.gov) - Feb 4, 2016
P1/2, N=43, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Jul 2016 Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: AXEPT: A Phase III Study of 2nd-line XELIRI (clinicaltrials.gov) - Feb 3, 2016
P3, N=650, Active, not recruiting, Sponsor: Epidemiological and Clinical Research Information Network
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date: A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer (clinicaltrials.gov) - Feb 3, 2016
P2, N=180, Recruiting, Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Dec 2017
- ||| BNT321 / BioNTech
New P1 trial, Monotherapy: MV-0715-CP-001.01: Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies (clinicaltrials.gov) - Feb 3, 2016
P1, N=62, Recruiting, Sponsor: MabVax Therapeutics, Inc.
- Trial completion, Metastases: FLOT3: Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (clinicaltrials.gov) - Feb 3, 2016
P2, N=252, Completed, Sponsor: Krankenhaus Nordwest
Trial primary completion date: Dec 2015 --> Dec 2017 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 2, 2016
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Oct 2015 --> Jan 2017
- | leucovorin calcium / Generic mfg.
Phase classification, Enrollment change, Trial primary completion date: ACTHYF: Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children (clinicaltrials.gov) - Feb 2, 2016
P3, N=175, Recruiting, Sponsor: Institut Jerome Lejeune
Trial primary completion date: Oct 2015 --> Jan 2017 Phase classification: P2/3 --> P3 | N=256 --> 175 | Trial primary completion date: May 2017 --> Sep 2017
- ||| monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
New P1 trial, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) - Feb 2, 2016
P1, N=208, Not yet recruiting, Sponsor: MedImmune LLC
- | futuximab/modotuximab (S95026) / Servier
Trial initiation date, Trial primary completion date, Combination therapy, Metastases: Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Feb 1, 2016
P1/2, N=50, Not yet recruiting, Sponsor: Symphogen A/S
Phase classification: P2/3 --> P3 | N=256 --> 175 | Trial primary completion date: May 2017 --> Sep 2017 Initiation date: Nov 2015 --> Mar 2016 | Trial primary completion date: Nov 2017 --> May 2018
- Zolinza (vorinostat) / Merck (MSD), Decadron (dexamethasone) / Merck (MSD), Oncaspar liquid (pegaspargase) / Servier
Phase classification: Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I (clinicaltrials.gov) - Feb 1, 2016
P1/2, N=50, Recruiting, Sponsor: St. Jude Children's Research Hospital
Initiation date: Nov 2015 --> Mar 2016 | Trial primary completion date: Nov 2017 --> May 2018 Phase classification: P2 --> P1/2
- | BMS-986142 / BMS
Trial completion: Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy Patients (clinicaltrials.gov) - Feb 1, 2016
P1, N=24, Completed, Sponsor: Bristol-Myers Squibb
Phase classification: P2 --> P1/2 Not yet recruiting --> Completed
- Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Enrollment change, Trial termination, Trial primary completion date: BOS2: Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases (clinicaltrials.gov) - Jan 30, 2016
P2, N=44, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting --> Completed N=360 --> 44 | Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Dec 2015; Low or poor accrual
- Trial primary completion date: Colon Neoadjuvant FOLFOXIRI Study (clinicaltrials.gov) - Jan 30, 2016
P2, N=40, Recruiting, Sponsor: Chinese University of Hong Kong
N=360 --> 44 | Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Dec 2015; Low or poor accrual Trial primary completion date: Oct 2015 --> Dec 2016
- Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Trial initiation date, Trial primary completion date: FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 29, 2016
P2, N=25, Not yet recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Oct 2015 --> Dec 2016 Initiation date: Sep 2015 --> Jul 2016 | Trial primary completion date: Jul 2017 --> Jul 2018
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma (clinicaltrials.gov) - Jan 26, 2016
P1, N=18, Recruiting, Sponsor: University of California, Davis
Initiation date: Sep 2015 --> Jul 2016 | Trial primary completion date: Jul 2017 --> Jul 2018 Not yet recruiting --> Recruiting
- Vectibix (panitumumab) / Amgen
Trial completion, Enrollment change, Trial primary completion date: Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment (clinicaltrials.gov) - Jan 25, 2016
P1, N=74, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Completed | N=50 --> 74 | Trial primary completion date: Dec 2013 --> May 2013
- Trial primary completion date: A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jan 25, 2016
P2, N=50, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Recruiting --> Completed | N=50 --> 74 | Trial primary completion date: Dec 2013 --> May 2013 Trial primary completion date: Apr 2015 --> Apr 2017
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jan 25, 2016
P1, N=21, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Apr 2015 --> Apr 2017 Recruiting --> Active, not recruiting | N=15 --> 21 | Trial primary completion date: Apr 2016 --> Jan 2016
- || AL101 / Ayala Pharma
Combination therapy, Metastases: Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors (clinicaltrials.gov) - Jan 25, 2016
P1, N=95, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting | N=15 --> 21 | Trial primary completion date: Apr 2016 --> Jan 2016 Recruiting --> Active, not recruiting
- || Cyramza (ramucirumab) / Eli Lilly
New P2/3 trial, Combination therapy: FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) (clinicaltrials.gov) - Jan 25, 2016
P2/3, N=908, Not yet recruiting, Sponsor: Krankenhaus Nordwest
- |||| oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg.
Trial completion, Trial primary completion date: Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ) (clinicaltrials.gov) - Jan 22, 2016
P2, N=58, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jan 2018 --> Jan 2016
- Avastin (bevacizumab) / Roche
Enrollment change, Combination therapy: FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer (clinicaltrials.gov) - Jan 22, 2016
P1/2, N=35, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Active, not recruiting --> Completed | Trial primary completion date: Jan 2018 --> Jan 2016 N=25 --> 35
- |||| Jakafi oral (ruxolitinib) / Novartis, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 21, 2016
P2, N=92, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=25 --> 35 Active, not recruiting --> Recruiting